Nephrol Dial Transplant (2000) 15: 867-871
© 2000 European Renal Association-European Dialysis and Transplant Association
Tacrolimus reversibly reduces insulin secretion in paediatric renal transplant recipients
1 Department of Paediatric Nephrology, 2 Division of Paediatric Endocrinology, Charité Children's Hospital and 3 Department of Nephrology, Humboldt University, Berlin, Germany
Background. Conflicting reports exist about the mechanism of tacrolimus-induced post-transplant diabetes mellitus.
Methods. We analysed intravenous glucose tolerance tests (IVGTT) of 14 paediatric renal transplant recipients on cyclosporin (CsA) microemulsion and 15 patients on tacrolimus (FK506). The groups were similar in age (13.2±4.2 vs 13.0±3.7 years), body mass index, serum creatinine concentrations (96±60 vs 97±44 µmol/l), time after renal transplantation, and cumulative steroid dose over 12 weeks prior to the test (3.4 vs 3.5 mg/m2/day, NS, Mann–Whitney). Parameters of glucose tolerance included glucose, insulin, C-peptide concentrations, and HbA1c. The mean concentrations of the primary immunosuppressant were similar to treatments employed in other centres (CsA 165±59 ng ml and FK506 7.5±2.2 ng ml).
Results. Baseline glucose concentrations were significantly higher on FK506 therapy compared with CsA microemulsion therapy. Baseline insulin concentrations and C-peptide concentrations were identical in both treatment groups. FK506 trough levels correlated negatively with k values (glucose constant decay) in the FK506 group. There was a significant reduction of the insulin first-phase concentrations, both after 1 min and after 3 min in the FK506 group compared with the CsA group (112±17 vs 237±57 µU/ml, P=0.034). In patients with repetitive IVGTTs, glucose constant decay and insulin production improved after lowering FK506 whole-blood trough levels.
Conclusions. We conclude that post-transplant glucose intolerance could be due to a dose-dependent, direct effect of FK506 on the pancreatic beta cell function, which can be controlled by dose reduction.
Keywords: calcineurin inhibitors; cyclosporin microemulsion; glucose tolerance; insulin production; renal transplantation; tacrolimus
Correspondence and offprint requests to: Guido Filler MD FRCPC, Professor of Paediatrics, Head, Division of Paediatric Nephrology, Department of Paediatrics, University of Ottawa, 401 Smyth Road, Ottawa, Ontario, Canada K1H 8L1.
Present address: Department of Paediatrics, University of Ottawa, Ottawa, Canada.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  D. Jansson, A. C.-H. Ng, A. Fu, C. Depatie, M. Al Azzabi, and R. A. Screaton Glucose controls CREB activity in islet cells via regulated phosphorylation of TORC2 PNAS, July 22, 2008; 105(29): 10161 - 10166. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. F. Crutchlow and R. D. Bloom Transplant-Associated Hyperglycemia: A New Look at an Old Problem Clin. J. Am. Soc. Nephrol., March 1, 2007; 2(2): 343 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. G. Radu, S. Fujimoto, E. Mukai, M. Takehiro, D. Shimono, K. Nabe, M. Shimodahira, R. Kominato, Y. Aramaki, Y. Nishi, et al. Tacrolimus suppresses glucose-induced insulin release from pancreatic islets by reducing glucokinase activity Am J Physiol Endocrinol Metab, February 1, 2005; 288(2): E365 - E371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. R. Rickels, M. H. Schutta, J. F. Markmann, C. F. Barker, A. Naji, and K. L. Teff {beta}-Cell Function Following Human Islet Transplantation for Type 1 Diabetes Diabetes, January 1, 2005; 54(1): 100 - 106. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. Di Cosmo, P. Vajro, D. Debray, G. Valerio, M. Giugliano, P. Buono, and A. Franzese Normal {beta}-Cell Function in Post-Liver Transplantation Diabetes Treated With Tacrolimus Diabetes Care, July 1, 2004; 27(7): 1837 - 1838. [Full Text] [PDF]
|
|
|
|
 |
|
 M. E. Doyle and J. M. Egan Pharmacological Agents That Directly Modulate Insulin Secretion Pharmacol. Rev., March 1, 2003; 55(1): 105 - 131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. M. van Duijnhoven, M. H. L. Christiaans, J. M. M. Boots, F. H. M. Nieman, B. H. R. Wolffenbuttel, and J. P. van Hooff Glucose Metabolism in the First 3 Years after Renal Transplantation in Patients Receiving Tacrolimus versus Cyclosporine-Based Immunosuppression J. Am. Soc. Nephrol., January 1, 2002; 13(1): 213 - 220. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. M. V. DUIJNHOVEN, J. M. M. BOOTS, M. H. L. CHRISTIAANS, B. H. R. WOLFFENBUTTEL, and J. P. V. HOOFF Influence of Tacrolimus on Glucose Metabolism before and after Renal Transplantation: A Prospective Study J. Am. Soc. Nephrol., March 1, 2001; 12(3): 583 - 588. [Abstract] [Full Text]
|
|